Can't Miss Webinar—Lupus Nephritis: The ACR Guideline in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Gout and Crystalline Arthritis

Old Disease, New Tricks: A Novel Approach to Understanding Gout

Jason Liebowitz, MD, FACR  |  December 7, 2023

SAN DIEGO—Gout has sometimes been called the disease of kings, not only because of the fact that purine-rich foods were long affordable only to wealthier individuals, but also because the disease has been around since the monarchies that existed centuries ago. However, with groundbreaking research leading to a better understanding of gout, we can now…

How to Reduce Gout Flares

Keri Losavio  |  November 12, 2023

SAN DIEGO—If patients with gout keep their serum urate (SU) levels very low with urate-lowering therapy (ULT), they have fewer flares, according to a research abstract presented at ACR Convergence 2023.

FDA Approves Canakinumab to Treat Gout Flares

Michele B. Kaufman, PharmD, BCGP  |  November 3, 2023

Canakinumab has received FDA approval for the treatment of patients with acute gout flares.

3 AC&R Study Summaries: Fractures in Patients with SSc, Clinical Response in JIA, & TV & the Public Perception of Gout

Arthritis Care & Research  |  August 13, 2023

Fractures in Patients with SSc By Zsuzsanna McMahan, MD, MHS Why was this study done? To minimize disability due to systemic sclerosis (SSc), it’s important to prevent and manage complications. Many SSc complications and related medications may increase the risk for osteoporosis and fracture. We sought to identify modifiable risk factors for fracture in patients…

Pegloticase Plus Methotrexate Effective for Uncontrolled Gout

Glen Rodman  |  August 8, 2023

The 12-month results of the MIRROR study show pegloticase co-administered with methotrexate is beneficial for patients with uncontrolled gout.

Treat to Target Lowers the Risk of Fracture in Patients with Gout

Arthritis & Rheumatology  |  July 26, 2023

Using data from the U.K.’s Health Improvement Network, a primary care database, Wei et al. examined whether urate-lowering therapy (ULT) in a treat-to-target approach for patients with gout reduces the risk of fracture.

Tigulixostat Promising for Patients with Gout & Hyperuricemia

Arthritis & Rheumatology  |  June 28, 2023

In a dose-finding, clinical trial, Terkeltaub et al. examined the safety and efficacy of tigulixostat, a nonpurine xanthine oxidase inhibitor, for lowering the serum urate levels of patients with gout and hyperuricemia.

Point-of-Care Uric Acid Testing

Samantha C. Shapiro, MD  |  March 1, 2023

In June 2022, I listened to several presentations on gout at EULAR’s European Congress of Rheumatology. Most began with data confirming a sad truth that we, as rheumatology providers, are all aware of: too many patients are taking subtherapeutic doses of urate-lowering therapy (ULT).1,2 Recommendations from the American College of Physicians in 2017 advocated for…

3 AC&R Study Summaries: Treat to Target in Gout, Response to Biologics in Patients with JIA, & Rehabilitation Dose in Adults with RA

Arthritis Care & Research  |  February 14, 2023

Treat to Target in Gout Monitoring & achievement of target serum urate levels By Jing Li & Gabriela Schmajuk, MD, MS Why was this study done? The ACR’s 2020 guideline for the management of gout recommends using a treat-to-target (T2T) approach to lower serum urate (SU). Using the ACR’s RISE registry, we examined the use…

Gout & Excess Risk of Severe SARS-CoV-2 Infection

Arthritis & Rheumatology  |  January 3, 2023

In this large, population-based study, Xie et al. found that the risks of SARS-CoV-2 infection, 30-day hospitalization and 30-day death were higher among individuals with gout than individuals without gout in the general population, irrespective of COVID-19 vaccination status.

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 22
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2026 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences